Contact this trialFirst, we need to learn more about you.
Ergot Alkaloid
Dihydroergotamine for Migraine
Recruiting2 awardsPhase 3
Albuquerque, New Mexico
This trial will study the safety and tolerability of a new drug, STS101, for the acute treatment of migraines. The trial will last 12 months and will be conducted at multiple centers.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service